6th Obesity and NASH Drug Development Summit 2022
Evvnt Promotion / evvnt
29.11.2022 - 01.12.2022 Revere Hotel Boston Common, 200 Stuart Street, 02116 Boston, Massachusetts, USA
Time: 09:55 - 16:40
Temi della conferenza
The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders.
The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Annotazioni
Brochure: https://go.evvnt.com/1277295-3?pid=4832
Speakers: Allison Goldfine, Director, Translational Medicine Cardiometabolic Disease, Novartis, Andrew Billin, Senior Director Biomarker Sciences, Gilead, and more.
Brochure: https://go.evvnt.com/1277295-3?pid=4832
Speakers: Allison Goldfine, Director, Translational Medicine Cardiometabolic Disease, Novartis, Andrew Billin, Senior Director Biomarker Sciences, Gilead, and more.
Informazioni ed Iscrizioni:
https://go.evvnt.com/1277295-2?pid=4832
Ms. Jessica Durston
Medicina General
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."
